Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.
J Clin Oncol · 2025-May · PMID 39772884
OS
FIG 2. OS in patients with (A) nonvisceral or (B) visceral disease a and exploratory analysis in patients with nonvisceral and visceral disease a in the (C) fulvestrant and (D) anastrozole arms. a Visceral disease was defined by the presence of tumors in the adrenal glands, bladder, CNS, esophagus, liver, lung, peritoneum, pleura, kidney, small bowel, stomach, pancreas, thyroid, colon, rectum, ovary, biliary tract, or spleen or by the presence of ascites, or pericardial or pleural effusion. b HR (fulvestrant:anastrozole) <1 favors fulvestrant. Crosses represent censored observations. Data cutoff: July 11, 2022. HR, hazard ratio; mOS, median OS; OS, overall survival.
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 2 | 2026-07-18T20:18:41+00:00 |